Abstract: This review discusses the isolation, structural elucidation, and biological activities of halogenated indole alkaloids obtained from marine invertebrates. Meridianins and related compounds (variolins, psammopemmmins, and aplicyanins), as well as alysinopsins and leptoclinidammines, are focused on. A compilation of the $^{13}$C-NMR spectral data of these selected natural indole alkaloids is also provided.

Keywords: marine invertebrates; halogenated indole alkaloids; structure elucidation; bioactivity; $^{13}$C-NMR spectral data

1. Introduction

Marine organisms are among the most promising sources of bioactive molecules [1–3]. Unlike terrestrial organisms, marine organisms often produce halogenated secondary metabolites, particularly alkaloids [4]. The majority of halogenated metabolites contain bromine and they are especially abundant in the marine environment, whereas chlorinated compounds are preferably synthesized by terrestrial organisms. In contrast to brominated and chlorinated metabolites, iodinated and fluorinated compounds are quite rare [5,6].

Marine life produces most of the 4,000 known natural organohalogens. Almost all of the 2,100 natural organobromine compounds are found in marine organisms. Although there is much less bromide than
chloride in the oceans (bromine 65 mg/L; chlorine 19,000 mg/L), marine organisms can oxidize bromide more easily for incorporation into organic compounds. Nevertheless, a large number of marine metabolites contain both bromine and chlorine [7,8].

Ecological pressures within the marine ecosystem, including significant competition for space, deterrence of predation, and a high level of symbiosis between different species, are partially responsible for the unique secondary metabolism of marine life that give rise to the chemical components of these actions and interactions [9,10].

The presence of halogen substituents in many natural products profoundly influences their biological activity [6]. Examples of such biologically active compounds are the antibiotics vancomycin, chloramphenicol aureomycin, and salinosporamide A; a proteasome inhibitor currently under clinical trials for multiple myeloma treatment; and the antimicrobial rebeccamycin [6,8].

Among halogenated alkaloids, bromoalkaloids are the most widely distributed group of natural compounds. This group is predominantly found in marine eukaryotes, is significantly rarer in prokaryotic microorganisms, and is practically absent from terrestrial plants and animals [4]. Iodoalkaloids compose a rare group of natural compounds that has been isolated from marine organisms [4].

The first iodinated indoles found in a natural source, either marine or terrestrial, were the plakohypaphorines A–C (1–3, Figure 1) isolated from the Caribbean sponge Plakortis simplex [8,11].

**Figure 1.** Structures of plakohypaphorines A, B, and C (1–3).

A huge diversity of indole alkaloids are frequently found in marine invertebrates and they have been considered lead compounds for the discovery of new drugs in medicinal chemistry [9,12]. The biological activity of marine indole alkaloids is clearly a product of the unique functionality and elements involved in the biosynthesis of marine natural products. For instance, bromination of many natural products has the potential to increase biological activity significantly [9].

In this report we have focused on the halogenated indole alkaloids from marine invertebrates, particularly meridianins; their related compounds variolins, psammopemmins, and aplicyanins as well as the aplysinopsins and leptoclinidamines. Also summarized are the methods of structure determination, observed biological activities and a compilation of $^{13}$C-NMR spectral data is provided.

### 1.1. Biohalogenation

The halogenation of natural products is a frequent modification of secondary metabolism that allows for optimization of the bioactivity of small molecules, providing evolutionary advantage [6].

Many biohalogenation enzymes have been isolated and characterized. Chloroperoxidase, bromoperoxidase, iodoperoxidase, and the enzymes involved in the biosynthesis of fluoroacetic acid (fluoroacetaldehyde dehydrogenase and 5’-fluorodeoxyadenosine synthase) are some examples [8].
Halogenating enzymes have been discovered in a broad range of organisms and they can be grouped into two main classes: (i) highly substrate-specific halogenases requiring dioxygen for enzymatic activity and (ii) less specific haloperoxidases (HPO) utilizing hydrogen peroxide. In dioxygen-dependent halogenases, either flavin (FADH$_2$-dependent halogenases) or R-ketoglutarate (non-heme FeII/R-ketoglutarate/O$_2$- dependent halogenases) are found to function as co-substrates. Furthermore, methyltransferases are involved in the formation of the carbon halogen bonds of CH$_3$Cl, CH$_3$Br, and CH$_3$I, and other enzymes requiring S-adenosyl-L-methionine as catalyst have been identified to be involved in fluorination and chlorination [13].

In the recent years, the understanding of biohalogenation processes has been extended extraordinarily. The cloning and sequencing of biosynthetic gene clusters have revealed new mechanisms leading to halogen incorporation and stimulated detailed mechanistic studies of these enzymes [6,8]. New groups of halogenating enzymes have been discovered and investigated at both biochemical and genetic levels. Each group of these enzymes performs halogenation reactions on chemically distinct substrates using a specific reaction mechanism. For instance, some FADH$_2$-dependent halogenases are directly involved in the halogenation of aromatic compounds, recognizing tryptophan or indole moieties, while other groups of FADH$_2$-dependent halogenases participate in the halogenation of aliphatic compounds [13].

1.2. Meridianins

Meridianins are marine alkaloids which were first isolated from the Ascidian *Aplidium meridianum* [14]. Structurally, the meridianins comprise a brominated and/or hydroxylated indole nucleus substituted at C-3 by a 2-aminopyrimidine. Seven meridianins A–G (4–10) have been discovered so far. Bromine substitution occurs on position 5 for meridianin C (6), on position 6 for B (5) and D (7), on position 7 for E (8), and on positions 5 and 6 for F (9) (Figure 2).

**Figure 2.** Structures of meridianins 4–10.

Meridianins have been described as potent inhibitors of various protein kinases (Table 1) and they display antitumor activity. Meridianins B (5) and E (8) are the most potent and, for this reason meridianin E was selected for further selectivity studies on 25 highly purified kinases [15]. Essentially, all physiological processes and most human diseases involve protein phosphorylation. Phosphorylation of proteins on serine, threonine, and tyrosine residues by the 518 protein kinases encoded in the human genome constitutes one of the major mechanisms used by cells to regulate their metabolism and functions. The recent appreciation of the implication of abnormal protein phosphorylation in many
human diseases has sparked considerable interest in the search for pharmacological inhibitors of kinases [16–18].

Table 1. Effects of meridianins A–G (4–10) on the activity of protein kinases (IC$_{50}$ in μM).

| Protein kinase |
|----------------|
| Meridianins     |
| A  | B  | C  | D  | E  | F  | G  |
| CDK1/cyclin B  | 2.50|  1.50 |  3.00 | 13.00 | 0.18 | 20.00 | 150.00 |
| CDK5/p25       | 3.00|  1.00 |  6.00 |  5.50 | 0.15 | 20.00 | 140.00 |
| PKA            | 11.00|  0.21 |  0.70 |  1.00 | 0.09 | 3.20 | 120.00 |
| PKG            | 200.0|  1.00 |  0.40 |  0.80 | 0.60 | 0.60 | 400.00 |
| GSK-3β         | 1.30|  0.50 |  2.00 |  2.50 | 2.50 | 2.00 | 350.00 |
| CK1            | nt  |  nt  |  30.00 | 100.00 | 0.40 | nt  | nt  |

1nt: not tested.

Protein phosphorylation regulates most aspects of cell life, whereas abnormal phosphorylation is a cause or consequence of diseases. For instance, among the 518 human kinases cyclin-dependent kinases (CDK) have attracted considerable interest given their involvement in many essential physiological pathways and numerous abnormalities in multiple human diseases, especially cancer and neurodegenerative diseases such as Alzheimer’s and Parkison’s diseases [16,18,19].

Investigations of structure-activity relationships of meridianins have revealed that the substitution at C-5 and the methylation of the indole nitrogen are important for either kinase inhibitory activity or in vitro antiproliferative activities. Related to CDK1 and CDK5, the bromine substitution on position 7 and the hydroxyl on position 4 provide the best inhibitory activity. A single bromine substitution on position 5 or 6 of the indole ring results in considerable improvement in potency. On the other hand, two bromide substitutions slightly reduce the inhibitory potency [20,21].

Meridianins B, C, D, and E (5–8) display cytotoxicity toward LMM3 (murine mammalian adenocarcinoma cell line) with IC$_{50}$ values of 11.4 μM, 9.3 μM, 33.9 μM, and 11.1 μM, respectively [14]. Certainly, meridianins constitute a new scaffold exhibiting micromolar inhibition of protein kinases from which more potent and selective inhibitors can be designed [15].

Meridianins are closely related to the variolins, a class of marine alkaloids from the Antarctic sponge Kirkpatrickia varialosa [22,23].

1.3. Variolins

In 1994, the Blunt, Munro and Faulkner laboratories reported the isolation and structural elucidation of the variolins from the rare Antarctic sponge Kirkpatrickia varialosa [22,23]. Variolins are the first examples of either terrestrial or marine natural products with a pyrido[3’,2’:4,5]pyrrolo[1,2-c]pyrimidine system. This rare pyridopyrrolopyrimidine skeleton has made the variolins an interesting class of alkaloids from both structural and biogenetic viewpoints. Variolins can also be considered as guanidine-based alkaloids in which the guanidine moiety is found in the guise of a 2-aminopyrimidine ring [24–26].

The isolated compounds included variolin A (11), variolin B (12), N(3’)-methyl tetrahydrovariolin B (13), and variolin D (14), the latter of which was reported to be an artifact of the extraction process.
produced by aerial oxidation of the variolins (Figure 3). This type of compounds exhibit a potent cytotoxic activity against P388 murine leukemia cell line, also being effective against Herpes simplex type I. Variolin B (12) is the most active of this family of natural products [26].

Figure 3. Structures of variolins 11–15.

There has been considerable interest in the synthesis of variolins due to the novelty of their structures, not to mention their biological properties and low natural occurrence [25]. To date, four total syntheses of variolin B have been reported in the literature [21,27–33], and the preparation of the synthetic deoxyvariolin B (15) has also been described [34,35]. The synthesis of new derivatives of variolin B with different substituents at positions C-5 and C-7 has also been reported [26].

Although the natural variolins isolated are not halogenated, this type of skeleton along with the structure of meridianins have been an inspiration for the synthesis of the hybrid meriolins 1–14 (16–29, Figure 4), including the halogenated meriolins 10 (25) and 11 (26) [18].

1.4. Meriolins

Variolins with a pyridopyrrolopyrimidine system and meridianins possessing a pyrimidyl-substituted indole skeleton bear some structural similarities. Through a combination of the common features of these natural products, a new class of 7-azaindole-containing analogues (16–29) known as meriolins has been designed by Meijer and co-workers [21].

Meriolins [3-(pyrimidin-4-yl)-7-azaindoles], a chemical hybrid of the variolins and meridianins, display potent inhibitory activity toward CDKs (especially CDK2 and CDK9). This class of compounds also exhibit better antiproliferative and proapoptotic properties in cell cultures compared with their ‘‘inspirational parent’’ molecules [18,19].
The resemblance between the chemical structures of the two natural products meridianins and variolin B has inspired the synthesis of a hybrid structure referred to as meriolins, which display better antiproliferative and proapoptotic properties in human tumor cell cultures than their parent molecules. A selectivity study performed on 32 kinases has shown that, compared with variolin B, meriolins exhibit enhanced specificity toward CDKs, with marked potency on CDK2 and CDK9 [19].

The structures of pCDK2/cyclin A/meriolin 3, pCDK2/cyclin A/meriolin 5, and pCDK2/cyclin A/variolin B complexes have been determined by X-ray crystallography, which revealed that these inhibitors bind within the ATP binding site of the kinase, but in different orientations [18,19,21].

All synthesized meriolins 1–14, along with variolin B as a reference, were tested on seven purified protein kinases, namely CDK1/cyclin B, CDK2/cyclin A, CDK5/p25, CDK9/cyclin T, GSK-3δ/β, CK1δ/ε, and DYRK1A (Table 2). Structure-Activity studies complemented with the crystal structure have provided some clarification on the action mechanisms of these molecules on their CDK target [18].

### Table 2. Effects of variolin B (12) and meriolins 1(16), 10 (25), and 11 (26) on the activity of protein kinases (IC$_{50}$ in µM).

| Protein kinase   | Variolin B | Meriolin 1 | Meriolin 10 | Meriolin 11 |
|------------------|------------|------------|-------------|-------------|
| CDK1/cyclin B    | 0.06       | 0.78       | 0.24        | 2.20        |
| CDK2/cyclin A    | 0.08       | 0.09       | 0.06        | 1.3         |
| CDK5/p25         | 0.09       | 0.51       | 0.23        | 0.68        |
| CDK9/cyclin T    | 0.026      | 0.026      | 0.05        | 1.00        |
| GSK-3α/β         | 0.07       | 0.63       | 2.00        | 30.0        |
| CK1              | 0.005      | 0.2        | 3.0         | 1.3         |
| DYRK1A           | 0.08       | 0.13       | 0.13        | 0.3         |

In the case of meriolin 11 (26), addition of a bromide atom at C-5 leads to a drop in inhibitory activity for almost all tested protein kinases, but this effect is particularly pronounced against CDK9 and GSK-3. CDK1, CDK2, and CDK5 are less affected by the bromide addition. Moreover, addition of a chloride atom at C-4 in meriolin 10 (25) results in decreased potency compared to the non-halogenated meriolin 1 (16). Taken together, these observations suggest that meriolins constitute a
new CDK inhibitory scaffold with promising antitumor activity, and they can be derived from molecules initially isolated from marine organisms [19].

1.5. Psammopemmins

Psammopemmins represent an unusual group of natural products isolated as an amine salt from an Antarctic marine sponge *Psammopemma* sp and they comprise three structurally related compounds designated psammopemmins A–C (30–32, Figure 5). All of the psammopemmins incorporate the 4-hydroxyindole moiety substituted at the 3-position by an unusual 2-bromopyrimidine system. Compounds containing 4-oxygenated indoles often display potent pharmacological properties. Psammopemmins B (31) and C (32) contain further bromination on the indole ring. Unfortunately, the small amounts of material isolated so far have precluded any further investigation of their biological activity. The assigned structure of the psammopemmin family likewise remains to be confirmed by total synthesis [21,36].

![Figure 5. Structures of psammopemmins 30–32 and aplycianins 33–38.](image)

1.6. Aplycianins

A new family of indole alkaloids was recently isolated from the Antarctic tunicate *Aplidium cyaneum* by Reyes and co-workers [37]. The aplycianins A–F (33–38, Figure 5) contain a bromoindole nucleus and a 6-tetrahydropyrimidine substituent at C-3. The main structural variations present in aplycianins include additional bromination of indole ring and the presence of *N*-methoxy group as shown in aplycianins C–F (35–38). The aplycianins share a common 3-(pyrimid-4-yl)indole structure with meridianins A–G (4–10), the psammopemmins A–C (30–32) and variolins A–D (11–14). The tetrahydropyrimidine system of the aplycianins has a stereocenter at C 4’, in contrast with the planar pyrimidine ring of the meridianins [21].

Aplycianins are cytotoxic to the human tumor cell lines MDA-MB-231 (breast adenocarcinoma), A549 (lung carcinoma), and HT-29 (colorectal carcinoma). They also exhibit antimitotic activity [38]. Lastly, given the high cytotoxicity typical of bromoindole derivatives, the presence of a bromoindole moiety in some aplycianins warrants their investigation as anticancer drugs. Recently, the first total synthesis of (±)-aplycianins A, B, and E and 17 analogues has been reported [38].
Regarding the aplicyanin family of indole alkaloids, the six variants of aplicyanins isolated were evaluated for cytotoxicity against a panel of three human tumor cell lines, colon (HT-29), lung (A-549), and breast (MDA-MB-231). The antimitotic activity of these variants has also been assessed. Cytotoxic activity in the submicromolar range as well as antimitotic properties have been found for aplicyanin B \((34)\), D \((36)\), and F \((38)\), with IC\(_{50}\) values in the low to sub-µM range. On the other hand, aplicyanin A \((33)\) and C \((35)\) proved to be inactive at the highest concentrations tested, whereas aplicyanin E \((37)\) displayed weak cytotoxic properties (Table 3). These results indicate a key role for the presence of the acetyl group in the biological activity of the aplicyanin family [37].

Table 3. Cytotoxicity (GI\(_{50}\) values reported in µM) and antimitotic activity (IC\(_{50}\), mM) of aplicyanins B \((34)\), D \((36)\), E \((37)\), F \((38)\) and (+) aplicyanin A, B, and E.

| Compound          | Cell lines | Antimitotic Activity |
|-------------------|------------|-----------------------|
|                   | A-549 | HT-29 | MDA-MB-231 |                          |
| Aplicyanin B      | 0.66  | 0.39  | 0.42   | 1.19                       |
| Aplicyanin D      | 0.63  | 0.33  | 0.41   | 1.09                       |
| Aplicyanin E      | 8.70  | 7.96  | 7.96   | nt\(^2\)                   |
| Aplicyanin F      | 1.31  | 0.47  | 0.81   | 0.18–0.036                 |
| (+)-aplicyanin A  | 0.27  | 0.11  | 0.27   | nt                         |
| (+)-aplicyanin B  | 0.51  | 0.33  | 0.98   | nt                         |
| (+)-aplicyanin E  | na\(^1\) | na | 10.9 | nt                         |

\(^1\)na: not active; \(^2\)nt: not tested.

In order to establish the structure-activity relationships of the aplicyanins, the total synthesis of (+)-aplycianins A, B, and E, plus 17 analogues was carried out by Sisa and co-workers in 2009 [38]. The compounds were again screened for cytotoxicity against the same three human tumor cell lines used for the natural compounds. Racemic (+)-aplicyanin A exhibited activity in the submicromolar range, despite the inactivity of the corresponding natural product. Racemic (+)-aplicyanin B was as active as its corresponding natural product in all three tested cellular lines, whereas aplicyanin E maintained the activity only towards the MDA-MB-231 cell line (Table 3). The decreased cytotoxicity observed for racemic aplicyanin E compared to the natural product, indicates that one enantiomer is more active than the other [38].

Fourteen of the synthesized compounds also exhibited considerable cytotoxic activity, and these results suggest that the bromine at position 5 of the indole nucleus strongly favors antiproliferative activity, and the acetyl group at the imine nitrogen also acts in some compounds. These results demonstrate the potential of aplycianins structure as a scaffold for anticancer drug discovery [38].

1.7. Aplysinopsins

In 1977, Kazlauskas, Rymantas, and co-workers reported the isolation of aplysinopsin \((39)\) from the dictyoceratid sponge *Aplysinopsis* [39,40]. Aplysinopsin derivatives belong to a class of indole alkaloids and they have also been found in other dictyoceratid and astrophorid sponges as well as in dendrophylliid scleractinian corals [41]. Additionally, aplysinopsins have been described in anemone, in a symbiotic association, and in a mollusk that feeds on the coral *Tubastrea coccinea* [39].
The halogenated alysinopsins natural derivatives (Figure 6) contain a 6-bromoindole moiety, and an iminoimidazolidinone or imidazolidinedione system, both varying in terms of the number and position of N-methylation. The iminoimidazolidinone portion of compounds 39–45 are shown as the exocyclic imino tautomer. Only compound 44 contains an additional bromine at the C-5 of the indole core. The alysinopsins derivatives also differ in terms of the presence and absence of the C-8-C-1′ double bond. Thus, alysinopsins with C-8-C-1′ double bonds, the most abundant type, can occur as two geometrical isomers (E/Z). Also, it has been observed that (Z)-aplysinopsins are generally less abundant than the (E)-isomers [41,42]. Aplysinopsins substituted at the nitrogen atom of the indole ring and dimers have also been isolated or identified, although compound 45 could be an artifact [43–45].

Alysinopsins exhibit cytotoxicity towards tumour cells, as well as some antimalarial and antimicrobial activities. However, properties related to neurotransmission modulation seem to be the most significant pharmacological feature of these compounds. Aplysinopsins have the potential to...
influence monoaminooxidase (MAO) and nitric oxide synthase (NOS) activities. They have also been found to modulate serotonin receptors [39].

Aplysinopsin-type compounds have been reported from multiple sources, with brominated aplysinopsins being described from sponges [46–49], corals [41–45], anemone, and mollusks [50,51]. Natural aplysinopsins differ in the bromination pattern of the indole ring. Almost all natural occurring aplysinopsins display halogenations at the position 6 of the indole ring. The only exception is the compound 5,6-dibromo-2’-demethylaplysinopsin (44), which an additional bromine atom at C-5 [39].

The compounds 6-bromo-2’-de-N-methylaplysinopsin (40) and 6-bromoaplysinopsin (41) isolated from the Jamaican sponge *Smenospongia auresia* displayed high-affinity [3H]antagonist binding from cloned human serotonin 5-HT2C receptors expressed in a mammalian cell line ($K_i = 2.3 \mu M$ and $K_i = 0.33 \mu M$, respectively). Compound 41 also displayed high-affinity [3H]antagonist binding from the 5-HT2A receptor subtype ($K_i = 2.0 \mu M$) compared with serotonin affinity values $K_i = 0.32 \mu M$ at the 5-HT2A receptor and $K_i = 0.13 \mu M$ at the 5-HT2C receptor [46].

The structure-activity relationship data reveal a role for the R1, R2, and R3 functional groups at positions 6, 2’, and 3’, respectively, in the binding to human serotonin 5-HT2 receptors. The length of the alkyl chain at the R3 position as well as the bromination at position R1 seems to be important for activity. In addition, bromination at the R1 position is also relevant for the binding affinity of aplysinopsins and for their selective binding to the 5-HT2C receptor subtype, since both compounds 40 and 41 are brominated and both selectively bind the 5-HT2C receptor subtype over the 5-HT2A receptor subtype. Methylation at the R2 position facilitates binding to the 5-HT2A receptor subtype. A larger number of analogues will be required to confirm this proposed structure-activity relationship [46]. Pharmacological and genetic studies have revealed that these receptors influence feeding, glucose homeostasis, and the energy efficiency of physical activity, sleep, sensory processing and learning, affective functioning, and the pathophysiology of several neuropsychiatric disorders [52,53].

6-Bromo-2’-de-N-methylaplysinopsin (40) and 6-bromoaplysinopsin (41) have also been tested *in vitro* against a D6 clone of *Plasmodium falciparum* for their *in vitro* antimalarial activity. 6-Bromoaplysinopsin (41) exhibited activity at 0.34 $\mu g/mL$ with selective index 14 (S.I. = [IC50 (Vero cells)/IC50 (P. falciparum)]), while 6-bromo-2’-de-N-methylaplysinopsin (40) showed moderate activity at 1.1 $\mu g/mL$ with low selectivity. Moreover, compound 40 inhibited the antimalarial target plasmepsin II enzyme with IC50 53 $\mu M$ (FRET) and 66 $\mu M$ (FP) [46].

Additionally, 6-bromoaplysinopsin (41) has been reported to be involved in the symbiotic association between *Radianthus kuekentbali* (sea anemone) and *Amphiprum perideraion* (anemone fish) [50].

A number of aplysinopsin alkaloids have also been evaluated for their neuromodulatory activity in two types of nitric oxide synthase (NOS) isoforms. Nitric oxide (NO) is known to be an important second messenger having numerous functions which regulate many physiological processes; e.g., inflammation, blood pressure regulation, platelet adhesion, neurotransmission, and defense mechanisms. The biosynthesis of NO is catalyzed by nitric oxide synthase (NOS), which is classified into three isoforms: inducible NOS (iNOS), endothelial NOS (eNOS), and neuronal NOS (nNOS). Therefore, a selective inhibitor of NOS isoforms would be expected to have significant therapeutic potential as a neuromodulator [47]. 6-Bromo-2’-de-N-methylaplysinopsin (40) and the isomers 5,6-dibromo-2’-demethylaplysinopsin Z-44 and E-44 isolated from the sponge *Hyrtios erecta* display selective inhibitory activity against nNOS, with 100% inhibition of nNOS at 125 $\mu g/mL$ [47].
Compounds Z-44 and E-44 showed no inhibitory activity against iNOS. In turn, aplysinopsin 40 inhibited only 7.5% of iNOS activity at a concentration of 125 μg/mL [47].

Regarding the antimicrobial potential of halogenated aplysinopsins, Koh and Sweatman [54] have reported the screening of the Australian coral Tubastrea faulkneri extract for antimicrobial assay against seven species of microbes (Vibrio alginolyticus, V. harveyi, V. parahaemolyticus, Photobacterium damsela, Alteromonas rubra, Staphylococcus aureus, and Synechococcus sp). Aplysinopsin (39), 6-bromoaplysinopsin (41), 6-bromo-2’-de-N-methylaplysinopsin (40), and its dimer 52 were the compounds isolated accounting for 72% of the activity of the T. faulkneri methanol extract. This study also suggested that these aplysinopsins are toxic to the larvae of other coral species that are potential competitors and could act as allelochemicals [54]. The aplysinopsins 46–49 isolated from the sponge Thorectandra sp were evaluated for antimicrobial activity against Staphylococcus epidermidis. All of the compounds were found to have either weak or moderate minimum inhibitory concentrations (MIC) ranging from 6.25 to 100 μg/mL as compared to the standard vancomycin (0.625 μg/mL) [48].

1.8. Leptoclinidamines

Three new indole alkaloids, namely leptoclinidamines A–C (54–56, Figure 7), have been recently isolated from the Australian ascidian Leptoclinides durus [55].

![Figure 7. Structures of leptoclinidamines 54–56.](image)

The leptoclinidamines A (54) and B (55) both contain an indoleglyoxylic acid attached to an L-arginine residue, while leptoclinidamine C (56) contains the rare 1,3-dimethyl-5-(methylthio)histidine moiety attached to a 6-bromoindole-3-carboxylic acid. The structure of leptoclinidamide A was confirmed by total synthesis. The compounds were tested for bioactivity against chloroquine-sensitive and chloroquine-resistant strains of the malarial parasite Plasmodium falciparum, for trypanosomal activity against Trypanosoma brucei, and for cytotoxicity against the cancerous cell line HeLa and noncancerous HEK 293 cells, but none of the compounds were bioactive [55].
1.9. Chartelline, Chartellamide, Securamines and Securines

Chartelline A, Chartellamide A, B and C (57–59, Figure 8) are unusual β-lactam-imidazole alkaloids isolated from the marine bryozoans Chartella papyracea (Flustridae) [56,57]. In addition, other halogenated indole-imidazole alkaloids named securamines were isolated from Securiflustra securifrons (Pallas), another member of this family. The halogenated securamines B (61) and C (62) only differ from securamines A (60) and D (63), respectively by the presence of a bromine substituent in the benzene ring [58]. Securamines E (64), F (65) and G (68) were isolated from the same bryozoans S. securifrons (Pallas) [59]. Securine A (66) and B (67) were obtained by dissolving securamine A (60) and B (61), respectively, in DMSO-\textit{d}_6 [59].
Table 4. Comparison of the biological activity of the main natural halogenated indole alkaloids meridianins, psammopemmins, aplicyanins, and aplysinopsins.

| Compound                                | Biological Activity                                                                 |
|-----------------------------------------|-------------------------------------------------------------------------------------|
| **Meridianins**                         |                                                                                    |
| Meridianin B (5)                        | Inhibition of protein kinases; Cytotoxicity [14,15]                                 |
| Meridianin C (6)                        | Inhibition of protein kinases; Cytotoxicity [14,15]                                 |
| Meridianin D (7)                        | Inhibition of protein kinases; Cytotoxicity [14,15]                                 |
| Meridianin E (8)                        | Inhibition of protein kinases; Cytotoxicity [14,15]                                 |
| Meridianin F (9)                        | Inhibition of protein kinases [14]                                                 |
| **Psammopemmins**                      |                                                                                    |
| Psammopemminin B (31)                   | nt ¹                                                                                |
| Psammopemminin C (32)                   | nt                                                                                  |
| **Aplicyanins**                         |                                                                                    |
| Aplicyanin A (33)                       | na ²                                                                               |
| Aplicyanin B (34)                       | Cytotoxicity and antimitotic activity [37]                                          |
| Aplicyanin C (35)                       | na                                                                                  |
| Aplicyanin D (36)                       | Cytotoxicity and antimitotic activity [37]                                          |
| Aplicyanin E (37)                       | Cytotoxicity [37]                                                                  |
| Aplicyanin F (38)                       | Cytotoxicity and antimitotic activity [37]                                          |
| **Aplysinopsins**                       |                                                                                    |
| 6-bromo-2'-de-N-methylaplysinopsin (40) | Antimalarial [46]; Serotonin receptors modulator [46]                               |
|                                         | Inhibitor of nitric oxide synthase (nNOS) [47]                                      |
| 6-bromoaplysinopsin (41)                | Antimalarial [46]; Serotonin receptors modulator [46]                               |
|                                         | Allochemical [54]                                                                  |
| 6-bromo-4'-de-N-methylaplysinopsin (42) | nt                                                                                  |
| 6-bromo-4'-demethyl-3'-N-methylaplysinopsin (43) | nt |
| 5,6-dibromo-2'-demethylaplysinopsin (44) | Inhibitor of nitric oxide synthase (nNOS) [47]                                      |
| 6-bromo-1',8-dihydro-aplysinopsin (46)  | Antimicrobial [48]                                                                 |
| 6-bromo-1'-hydroxy-1',8-dihydroaplysinopsin (47) | Antimicrobial [48] |
| 6-bromo-1'-methoxy-1',8-dihydroxyaplysinopsin (48) | Antimicrobial [48] |
| 6-bromo-1'-ethoxy-1',8-dihydroxyaplysinopsin (49) | Antimicrobial [48] |
| 6-bromo-3'-deimino-3'-oxoaplysinopsin (50) | nt |
| 6-bromo-3'-deimino-2',4'-bis(demethyl)-3'- | nt                                                                                 |
| Oxoaplysinopsin (51)                    |                                                                                    |
| Dimer of 6-bromo-2'-de-N-methylaplysinopsin (52) | Antimicrobial [54] |
| Tubastrindole A (53)                    | -                                                                                  |

¹ nt: not tested. ² na: not active.

1.10. Structural Elucidation

This section reports a compilation of the $^{13}$C chemical shifts of the halogenated marine indole alkaloids derivatives, meridianins (5–9), psammopemmins (30 and 32), aplicyanins (33–38), aplysinopsins (40–41, 43–44, 46–51, 53), and leptoclinidamines (56), which have in common the presence of a 3-substituted indole nucleus. Additionally, the $^{13}$C data of 10 and 39 are presented for comparison of the $^{13}$C chemical shifts with halogenated examples. The literature data are listed in Tables 5, 6, 7 and 8. The solvent (A = DMSO-$d_6$, B = CD$_3$OD, and C = CDCl$_3$) and references are shown in the first line of the tables.

Inspection of the $^{13}$C-NMR data of compounds 5, 8, 30 and 32 as compared with 10 (Table 5) reveals that introduction of a hydroxyl group in the C-4 indole moiety results in downfield signals at the α carbon. Additionally, comparison of the $^{13}$C data of meridianin G (10), which bears only a
3-substituted indole core, with the other bromine indole derivatives shows that introduction of a bromine in the indole skeleton results in upfield signals at the α carbon.

The meridianin family skeleton can be recognized by the typical 1H-NMR signals, as for example, in the case of compound 10: a pair of doublet for the pyrimidine protons (δ 7.02 and 8.05, J = 5.5 Hz), together with a singlet for H-2, the typical pattern of a 3-substituted indole nucleus. The 13C-NMR downfield signals at δ C-2’, C-4’, and CH-6’ corroborate the presence of 2-aminopyrimidine at C-3 in compounds 5–10 [60].

The basic difference between the psammopemmins and the meridianins is the presence of a 5’-substituted 4’-amino-2’-bromopyrimidine at C-3 of the indole nucleus. The distinguishing 1H-NMR signals of the heterocyclic ring of the psammopemmins class can be recognized by the signals at δ 7.12 (d, J = 5.4 Hz) and 8.12 (br d, J = 5.4 Hz), attributed to the pyrimidine proton H-6’ and to NH at position 1’, as in the case of compound 30. The 13C-NMR downfield signals at δ C-2’, C-4’, and C-5’ confirm the presence of 5’-substituted 4’-amino-2’-bromopyrimidine [28].

The aplycianins’ 13C-NMR spectra differ from those of the meridianins and psammopemmins because of the presence of the signals due to a guanidine group at low field (C-2’) and three chemicals shifts at upfield, ascribed to C-4’(CH), C-5’ (CH2), and C-6’ (CH2). Additionally, the 1H-NMR coupling constants of the 6-tetrahydropyrimidine protons are important to establish the difference between aplycyanins, meridianins, and psammopemmins [37].

Aplysinopsins (39–41, 43–44), with the iminoimidazolidinonone substituted at the C-3 of the indole core, normally show a 1H-NMR spectrum with signals due to N-methyl groups in the range of δ 3.0 to 3.5 (s, 3H), as well as a singlet characteristic of an olefinic proton in the δ 6.38–6.46 range. The 13C NMR spectrum reveals the signals for two olefinic carbons C-8 (CH) and C-1’(C), methyl, guanidine, and amide carbonyl, as well as those of the indole ring, as already mentioned [43,47,48]. Analysis of the 13C data of 39, which bears a 3-substituted indole core, and comparison with data of the other bromine indole derivatives show that the presence of bromine in the indole moiety results in upfield signals at the carbon α.

The spectra of aplysinopsins (50–51) differ in terms of the signals at C-8, C-3’, and C-5’, if compared with data for 3-iminoimidazolidinonone, where C=NH (C-3’) is replaced by C=O (C-3’) [41].

The E or Z-configuration of the double bond at C-8 could be assigned on the basis of a 1H, 13C heteronuclear coupling constant. The coupling constant value obtained for the E isomer was larger than in the Z [41,42]. The geometry of the C-8-C-1’ olefin could be determined by comparison of the chemical shift of the H-2 proton and C-8 carbon. In the Z isomer, the δ values of C-8 and H-2 were upfield compared to the values obtained for the E isomer [41,42,47]. Aplysinopin type compounds without substituents at N-2’ are predominantly of Z configuration, whereas the converse is true for compounds bearing a methyl group at N-2’. Although it is important to note that, Z and E aplysinopin alkaloids undergo rapid isomerization [41,42,61].

Comparison of the 13C-NMR data of 46–49 with previous aplysinopsins reveals that the C-8 and C-1’ signals are shifted upfield according to R1 at C-1’, thereby confirming that the double bond at C-8-C-1’ is absent. Segraves and Crews considered that 48 and 49 are artifacts formed from 47 during the extraction process [48].
Table 5. \(^{13}\)C chemical shifts (δ in ppm) of meridianins, psammopemmins, and aplicyanins halogenated derivatives.

| Carbon | 5 | 6 | 7 | 8 | 9 | 10 | 30 | 32 | 33 | 34 | 35 | 36 | 37 |
|--------|---|---|---|---|---|----|----|----|----|----|----|----|----|
| Solvent | A | A | A | A | B | B | A | B | B | B | B | B | B |
| Ref. | 14 | 14 | 14 | 14 | 60 | 60 | 25 | 25 | 37 | 37 | 37 | 37 | 37 |
| 2 | 129.9 | 129.6 | 129.2 | 129.2 | 131.6 | 129.1 | 128.3 | 128.8 | 125.3 | 125.6 | 123.8 | 124.1 | 124.7 |
| 3 | 113.7 | 113.3 | 114.8 | 116.1 | 114.9 | 115.4 | 113.7 | 113.6 | 113.6 | 113.8 | 112.0 | 111.2 | 112.3 |
| 3a | 114.0 | 127.1 | 124.5 | 115.2 | 127.6 | 126.8 | 114.3 | 113.9 | 124.1 | 127.8 | 124.3 | 124.1 | 123.5 |
| 4 | 153.0 | 124.6 | 124.3 | 152.0 | 127.7 | 122.7 | 152.0 | 121.9 | 121.8 | 122.5 | 122.4 | 124.6 | 124.6 |
| 5 | 108.8 | 113.4 | 123.1 | 107.3 | 118.4 | 123.4 | 105.4 | 108.4 | 115.2 | 114.3 | 114.4 | 114.6 | 119.3 |
| 6 | 116.7 | 124.7 | 113.9 | 126.7 | 117.1 | 121.9 | 124.3 | 115.6 | 126.1 | 126.9 | 127.1 | 116.4 | 116.4 |
| 7 | 105.3 | 113.9 | 114.5 | 92.6 | 117.5 | 112.8 | 102.3 | 105.0 | 114.5 | 114.6 | 111.4 | 111.5 | 114.6 |
| 7a | 139.7 | 135.9 | 138.0 | 136.9 | 138.5 | 138.9 | 139.2 | 139.5 | 137.2 | 137.2 | 132.7 | 132.7 | 133.6 |
| 2' | 160.7 | 163.6 | 163.6 | 160.2 | 165.3 | 165.6 | 161.7 | 161.6 | 155.7 | 152.3 | 155.7 | 152.4 | 155.7 |
| 4' | 160.8 | 162.3 | 162.3 | 161.8 | 163.9 | 165.6 | 160.7 | 159.7 | 48.1 | 48.2 | 47.6 | 47.7 | 47.4 |
| 5' | 104.6 | 105.4 | 105.4 | 104.8 | 107.1 | 107.6 | 158.3 | 158.8 | 28.3 | 26.9 | 28.3 | 26.6 | 28.3 |
| 6' | 157.1 | 157.2 | 157.2 | 159.0 | 156.2 | 157.5 | 104.3 | 104.3 | 38.6 | 38.6 | 38.4 | 38.2 | 38.3 |
| CH₃CO | 173.9 | 174.0 |
| CH₃CO | 24.1 | 24.1 |
| OCH₃ | 66.8 | 66.7 | 67.0 |

Table 6. \(^{13}\)C chemical shifts (δ in ppm) for halogenated aplicyanin 38 and alysinopsins derivatives.

| Carbon | 38 | 39 | 40 (Z) | 40 (E) | 41 | 43 (Z) | 43 (E) | 44 (Z) | 44 (E) | 50 (E) | 51 (Z) | 51 (E) |
|--------|----|----|--------|--------|----|--------|--------|--------|--------|--------|--------|--------|
| Solvent | B | A | A | A | A | A | A | A | A | A | A | A |
| Ref. | 37 | 62 | 42 | 42 | 43 | 42 | 42 | 47 | 47 | 41 | 41 | 41 |
| 2 | 125.0 | 127.4 | 129.6 | 129.0 | 127.7 | 129.9 | 129.0 | 130.6 | 132.6 | 129.3 | 127.5 | 130.1 |
| 3 | 111.5 | 108.4 | 111.9 | 110.7 | 108.7 | 112.0 | 110.8 | 108.3 | 108.2 | 108.7 | 108.7 | 108.9 |
| 3a | 123.2 | 127.8 | 125.7 | 126.7 | 126.9 | 125.7 | 126.8 | 127.8 | 128.4 | 127.5 | 126.3 | 127.3 |
| Solvent | Ref. | Carbon | 38 | 39 | 40 (Z) | 40 (E) | 41 | 43 (Z) | 43 (E) | 44 (Z) | 44 (E) | 50 (E) | 51 (Z) | 51 (E) |
|---------|------|--------|----|----|--------|--------|----|--------|--------|--------|--------|--------|--------|--------|
| B       | 37   | A      | A  | A  | A      | A      | A  | A      | A      | A      | A      | A      | A      | A      |
| A       | 62   | 42     | 42 | 42 | 43     | 42     | 42 | 42     | 47     | 47     | 47     | 41     | 41     | 41     |
| 4       | 124.5| 118.1  | 121.0|119.9|119.6  |121.1  |120.0|123.6  |122.5  |120.2  |120.1  |119.2  |
| 5       | 119.5| 119.5  | 122.4|122.5|121.8  |122.4  |122.5|116.9  |116.9  |122.6  |122.9  |122.8  |
| 6       | 116.6| 121.8  | 114.5|114.4|121.8  |114.5  |114.5|115.2  |115.2  |114.0  |115.0  |114.6  |
| 7       | 114.6| 111.8  | 114.3|114.4|114.0  |114.3  |114.4|116.8  |117.2  |114.6  |114.4  |115.0  |
| 7a      | 133.6| 135.7  | 136.7|136.5|136.2  |136.5  |136.5|135.8  |135.8  |136.5  |136.5  |136.5  |
| 8       | 102.8| 106.1  | 113.3|101.5|106.5  |113.9  |108.9|115.1  |107.5  |101.0  |106.5  |
| 1'      | 126.5| 136.9  | 134.9|126.9|136.9  |136.6  |135.7|125.1  |124.9  |125.4  |
| 2'      |      |        |     |     |        |        |     |        |        |        |        |        |        | 152.3  |
| 3'      | 26.8 | 150.8  | 157.7|155.0|162.1  |157.1  |154.7|155.9  |152.7  |152.8  |155.4  |153.4  |
| 4'      | 47.6 |        |     |     |        |        |     |        |        |        |        |        |        |
| 5'      | 26.8 | 162.3  | 169.0|167.0|150.4  |169.0  |167.1|163.2  |160.8  |162.0  |167.3  |163.9  |
| 6'      | 38.1 |        |     |     |        |        |     |        |        |        |        |        |        |        |
| 2'-NCH3 |      | 27.0   |     |     |        |        |     |        |        |        |        |        |        | 24.3   |
| 4'-NCH3 |      |        |     |     |        |        |     |        |        |        |        |        |        |        |
| OCH3    |      | 67.1   |     |     |        |        |     |        |        |        |        |        |        |        |
| CH3CO   |      | 174.0  |     |     |        |        |     |        |        |        |        |        |        |        |
| CH3CO   |      | 24.1   |     |     |        |        |     |        |        |        |        |        |        |        |
**Table 7.** $^{13}$C chemical shifts (δ in ppm) for halogenated aplysinopsins and leptoclinidamines derivatives.

| Carbon  | 46 | 47 | 48 | 49 | 53 | 56 | Carbon  | 46 | 47 | 48 | 49 | 53 | 56 |
|---------|----|----|----|----|----|----|---------|----|----|----|----|----|----|
| Solvent | B  | B  | B  | B  | ni | A  | 4'      |    |    |    |    |    |    |
| Ref.    | 48 | 48 | 48 | 48 | 44 | 55 | 119.7   |    |    |    |    |    |    |
| 2       | 124.8 | 125.1 | 125.4 | 125.4 | 123.3 | 129.0 | 5'      | 171.8 | 171.9 | 169.7 | 170.0 | 124.8 |
| 3       | 106.5 | 105.3 | 104.6 | 104.7 | 115.0 | 109.4 | 6'      |       |       |       |       | 117.3 |
| 3a      | 125.7 | 125.6 | 125.6 | 125.6 | 126.4 | 124.9 | 7'      |       |       |       |       | 115.9 |
| 4       | 119.3 | 119.3 | 119.4 | 119.0 | 120.1 | 122.9 | 7a'     |       |       |       |       | 137.4 |
| 5       | 121.9 | 122.0 | 122.1 | 122.0 | 121.5 | 123.4 | 8'      |       |       |       |       | 44.5  |
| 6       | 114.7 | 114.8 | 114.9 | 114.9 | 125.9 | 114.6 | 9'      |       |       |       |       | 72.3  |
| 7       | 113.9 | 114.0 | 114.0 | 114.0 | 113.0 | 114.8 | 11'     |       |       |       |       | 159.0 |
| 7a      | 137.2 | 137.1 | 137.2 | 137.2 | 139.5 | 137.0 | 13'     |       |       |       |       | 172.5 |
| 8       | 29.4  | 30.1 | 30.1 | 30.4 | 27.6 | 164.1 | 2'-NCH$_3$ | 24.7 | 25.3 | 25.6 | 25.6 |
| 9       | 72.3  |      |      |      |      |      | 4'-NCH$_3$ | 24.1 | 24.6 | 24.7 | 24.6 |
| 10      |      |      |      |      |      |      | 10-NCH$_3$ | 50.0 |       |       |       | 33.1  |
| 11      |      |      |      |      |      |      | 12-NCH$_3$ | 25.7 |       |       |       | 26.6  |
| 12      |      |      |      |      |      |      | 13-SCH$_3$ | 136.4 | 18.6 |
| 13      |      |      |      |      |      |      | 14-NCH$_3$ | 125.9 | 33.5 |
| 15      |      |      |      |      |      |      | 16-NCH$_3$ | 138.1 | 34.2 |
| 17      |      |      |      |      |      |      | 10'-NCH$_3$ | 172.2 | 28.4 |
| 1'      |      |      |      |      |      |      | 12'-NCH$_3$ | 64.0  |       |       |       | 26.5  |
| 2'      |      |      |      |      |      |      | OCH$_3$ | 125.6 | 52.3 |
| 3'      |      |      |      |      |      |      | OCH$_2$ | 158.1 | 61.5 |
| 3'a     |      |      |      |      |      |      | CH$_3$ | 127.7 | 13.7 |

$^1$ ni: not informed.
| Carbon | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 |
|--------|----|----|----|----|----|----|----|----|----|----|----|
| Solvent |  |  |  |  |  |  |  |  |  |  |  |
| Ref.   |  |  |  |  |  |  |  |  |  |  |  |
| 2      | 120.4 | 120.6 | 127.4 | 127.1 | 135.9 | 136.1 | 136.4 | 135.9 | 130.2 | 130.3 | 48.3 |
| 3      | 109.5 | 108.1 | 95.1 | 95.3 | 101.6 | 101.2 | 101.2 | 101.5 | 100.9 | 103.6 | 96.3 |
| 4      | 130.5 | 130.8 | 115.8 | 116.0 | 187.5 | 188.0 | 187.3 | 187.2 | 121.1 | 121.5 | 140.7 |
| 6      | 133.2 | 116.6 | 122.5 | 121.1 | 166.6 | 166.7 | 166.4 | 166.0 | 125.0 | 127.6 | 156.8 |
| 8      | 126.6 | 129.5 | 145.5 | 144.8 | 85.6 | 85.7 | 85.4 | 84.7 | 135.6 | 135.3 | 80.7 |
| 9      | 65.9 | 65.2 | 41.6 | 41.9 | 44.0 | 43.9 | 44.2 | 43.7 | 40.6 | 40.8 | 39.2 |
| 10     | 41.6 | 41.6 | 64.9 | 64.6 | 59.4 | 59.5 | 58.7 | 52.1 | 71.2 | 70.9 | 61.4 |
| 11     | 45.9 | 46.8 | 48.6 | 48.3 | 41.8 | 41.7 | 41.9 | 42.8 | 30.8 | 30.8 | 41.0 |
| 12     | 67.9 | 70.5 | 87.4 | 87.4 | 89.2 | 89.1 | 88.0 | 89.8 | 132.7 | 133.9 | 87.9 |
| 14     | 141.5 | 141.1 | 147.0 | 148.0 | 147.0 | 145.7 | 148.0 | 146.9 | 134.4 | 134.5 | 147.5 |
| 15     | 117.6 | 117.6 | 109.3 | 112.2 | 114.7 | 111.1 | 113.5 | 114.7 | 110.9 | 113.2 | 114.6 |
| 16     | 125.9 | 126.0 | 129.0 | 122.3 | 123.1 | 129.4 | 120.6 | 123.0 | 120.5 | 114.1 | 122.3 |
| 17     | 132.5 | 132.5 | 119.9 | 122.5 | 124.9 | 121.9 | 128.0 | 124.9 | 118.1 | 119.4 | 123.5 |
| 18     | 119.4 | 119.4 | 123.9 | 125.0 | 125.6 | 124.6 | 123.8 | 125.5 | 117.5 | 121.1 | 125.2 |
| 19     | 124.8 | 124.7 | 127.8 | 126.7 | 128.0 | 128.8 | 126.3 | 127.9 | 128.5 | 126.0 | 130.4 |
| 20     | 67.4 | 67.6 | 50.0 | 49.4 | 45.0 | 45.3 | 46.8 | 44.9 | 105.7 | 106.3 | 45.6 |
| 21     | 47.8 | 48.0 | 34.1 | 33.8 | 34.2 | 34.4 | 32.6 | 34.2 | 30.7 | 30.6 | 33.8 |
| 22     | 162.5 | 162.1 | 172.8 | 172.2 | 170.3 | 170.5 | 170.0 | 170.0 | 169.4 | 169.1 | 171.2 |
| 23     | 164.9 | 164.1 | 19.0 | 18.9 | 17.2 | 17.3 | 17.1 | 18.6 | 19.8 | 19.8 | 15.4 |
| 24     | 15.4 | 17.1 | 31.9 | 31.8 | 21.1 | 21.1 | 21.1 | 22.6 | 28.7 | 28.7 | 21.1 |
The $^{13}$C-NMR data of compound 53 indicates the presence of two indoles and two iminoimidazolidinones. Biogenetically, this compound could be formed from an enzymatic Diels–Alder cycloaddition of two molecules of aplysinopsin, which were probably derived from tryptophan and guanidine, followed by some modifications [44].

The structure of leptoclinidamine C (56) has been established as a 3,6-disubstituted indole and a $\beta$-substituted alanine by 1D and 2D NMR data. The $^{13}$C data indicate the presence of two N-methyl groups at C-14 and C-16; a third methyl group at C-13 is attributable to an S-methyl. As mentioned, the chemical shift of the quaternary carbon C-6 ($\delta$ 114.6) indicates that the bromine was substituted at this position [55].

2. Conclusions

In recent decades the number of new isolated natural compounds, many of which contain halogen, has increased significantly as a consequence of improved collection methods (scuba diving and remote submersibles for accessing deep water organisms), selective bioassays, new separation and purification techniques, and powerful identification methods such as multi-dimensional NMR spectroscopy, high-resolution mass spectrometry, and X-ray diffraction [8,3]. The assignment of carbon signals of a given isolated compound by comparison with the data of known compounds is an important tool for the discovery of novel natural compounds, when the $^{13}$C-NMR data of appropriate model compounds are available. This was the case with meridianins A–E, which were deduced by 2D NMR spectroscopic methods in combination with comparison to literature data reported for the related natural products the psammopemmins. The indole alkaloids are a class of marine natural products displaying unique promising properties for the development of new drug leads, and they are a wonderful challenge to synthetic chemists. The majority of marine indole alkaloids are rather simple compounds. However, some of the indole alkaloids carry unique structural features. Bacteria and algae have yielded simple halogenated indoles, while more complicated structures have been isolated from marine sources [9]. Over the past 5 years there has clearly been an increasing interest in the isolation, determination of the biological and ecological significance, and synthesis of meridianins, aplysinopsis, and analogues, as confirmed by number of articles and reviews about these marine natural molecules [21,39,63]. Among the different classes of compounds reported here, the protein kinase inhibitors meridianins deserve prominence. Along with variolins, these compounds have inspired the design of the synthetic hybrid meriolins, which constitute a new CDK inhibitory scaffold with promising antitumor activity. On the other hand, aplycianins because of their pronounced antimitotic and cytotoxic potential, have been considered a novel model for anticancer drug discovery. Unfortunately, the biological potential of psammopemmins and the recently isolated leptolinidamines are unknown so far. Finally, aplysinopsins show specific toxicity for cancer cells; however, the most potent pharmacological activity of aplysinopsins is related to modulation of the central nervous system. An interesting fact in all these types of indole skeletons covered here is that halogenations generally occur at C-5, sometimes at C-6, or at both C-5 and C-6 of the indole ring. The bromination of many of the mentioned natural products could be associated with increased biological activity [9].
Acknowledgements

CNPq (The National Council for Scientific and Technological Development) is acknowledged for Research Productivity Fellowships granted to A.A.S.F., M.L.A.S., W.R.C. and A.H.J. C.G.B. and L.S.C. were supported by FAPESP (São Paulo Research Foundation) scholarships.

References

1. Blunt, J.W.; Copp, B.R.; Munro, M.H.G.; Northcote, P.T.; Prinsep, M.R. Marine natural products. *Nat. Prod. Rep.* **2005**, *22*, 15–61.
2. Blunt, J.W.; Copp, B.R.; Hu, W.-P.; Munro, M.H.G.; Northcote, P.T.; Prinsep, M.R. Marine natural products. *Nat. Prod. Rep.* **2009**, *26*, 170–244.
3. Bhakuni, D.S.; Rawat, D.S. *Bioactive Marine Natural Products*, 1st Ed.; Springer: Anamaya, India, 2005; pp. 100–269.
4. Dembitsky, V.M. Bromo-and iodo-containing alkaloids from marine microorganisms and sponges. *Russ. J. Bioorg. Chem.* **2002**, *28*, 170–182.
5. Kling, E.; Schmid, C.; Unversucht, S.; Wage, T.; Zehner, S.; van Pee, K.-H. Enzymatic incorporation of halogen atoms into natural compounds. In *Biocombinatorial Approaches for Drug Finding* (Ernst Schering Foundation Symposium Proceedings); Wohlleben, W., Spellig, T., Müller-Tiemann, B., Eds.; Springer: Berlin Heidelberg, Germany, 2005; Volume 51, pp. 165–194.
6. Neumann, C.S.; Fujimori, D.G.; Walsh, C.T. Halogenation strategies in natural product biosynthesis. *Chem. Biol.* **2008**, *15*, 99–109.
7. Gribble, G.W. The diversity of naturally occurring organobromine compounds. *Chem. Soc. Rev.* **1999**, *28*, 335–346.
8. Gribble, G.W. Natural organohalogens: A new frontier for medicinal agents? *J. Chem. Educ.* **2004**, *81*, 1441–1449.
9. Gul, W.; Hamann, M.T. Indole alkaloid marine natural products: An established source of cancer drug leads with considerable promise for the control of parasitic, neurological and other diseases. *Life Sci.* **2005**, *78*, 442–453.
10. König, G.M.; Wright, A.D.; Sticher, O.; Angerhofer, C.K.; Pezzuto, J.M. Biological activities of selected marine natural products. *Planta Med.* **1994**, *60*, 532–537.
11. Campagnuolo, C.; Fattorusso, E.; Tagliatela-Scafati, O. Plakohypophorines A-C, iodine-containing alkaloids from the Caribbean Sponge *Plakortis simplex*. *Eur. J. Org. Chem.* **2003**, 284–287.
12. Frederich, M.; Tits, M.; Angenot, L. Potential antimalarial activity of indole alkaloids. *Trans. R. Soc. Trop. Med. Hyg.* **2008**, *102*, 11–19.
13. Wagner, C.; Omari, M.E.; König, G.M. Biohalogenation: Nature’s way to synthesize halogenated metabolites. *J. Nat. Prod.* **2009**, *72*, 540–553.
14. Franco, L.H.; Joffé, E.B.deK.; Puricelli, L.; Tatian, M.; Seldes, A.M.; Palermo, J.A. Indole alkaloids from the Tunicate *Aplidium meridianum*. *J. Nat. Prod.* **1998**, *61*, 1130–1132.
15. Gompel, M.; Leost, M.; Joffé, E.B.D.K.; Puricelli, L.; Franco, L.H.; Palermoc, J.; Meijera, L. Meridianins, a new family of protein kinase inhibitors isolated from the Ascidian *Aplidium meridianum*. *Bioorg. Med. Chem. Lett.* **2004**, *14*, 1703–1707.
16. Cohen, P. Protein kinases-the major drug targets of the twenty-first century? Nat. Rev. Drug Discov. 2002, 1, 309–315.
17. Noble, M.E.M.; Endicott, J.A.; Johnson, L.N. Protein Kinase inhibitors: Insights into drug design from structure. Science 2004, 303, 1800–1805.
18. Echalier, A.; Bettayeb, K.; Ferandin, Y.; Lozach, O.; Clément, M.; Valette, A.; Liger, F.; Marquet, B.; Morris, J.C.; Endicott, J.A.; Joseph, B.; Meijer, L. Meriolins (3-(Pyrimidin-4-yl)-7-azaindoles): Synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/Cyclin A/Meriolin complex. J. Med. Chem. 2008, 51, 737–751.
19. Bettayeb, K.; Tirado, O.M.; Marionneau-Lambot, S.; Ferandin, Y.; Lozach, O.; Morris, J.C.;Mateo-Lozano, S.; Drueckes, P.; Schächtele, C.; Kubbutat, M.H.G.; Liger, F.; Marquet, B.; Joseph, B.; Echalier, A.; Endicott, J.A.; Notario, V.; Meijer, L. Meriolins, a new class of cell death-inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases. Cancer Res. 2007, 67, 8325–8334.
20. Gedu, R.A.; Debiton, E.; Ferandin, Y.; Meijer, L.; Prudhomme, M.; Anizon, F.; Moreau, P. Synthesis and biological activities of aminopyrimidyl-indoles structurally related to meridianins. Bioorg. Med. Chem. 2009, 17, 4420–4424.
21. Walker, S.R.; Carter, E.J.; Huff, B.C.; Morris, J.C. Variolins and related alkaloids. Chem. Rev. 2009, 109, 3080–3098.
22. Perry, N.B.; Ettouati, L.; Litaudon, M.; Blunt, J.W.; Munro, M.H.G.; Parkin, S.; Hope, H. Alkaloids from the antarctic sponge Kirkpatrickia varialosa. Part 1: Variolin B, A new antitumour and antiviral compound. Tetrahedron 1994, 50, 3987–3992.
23. Trimurtulu, G.; Faulkner, D.J.; Perry, N.B.; Ettouati, L.; Litaudon, M.; Blunt, J.W.; Munro, M.H.G.; Jameson, G.B. Alkaloids from the antarctic sponge Kirkpatrickia varialosa. Part 2: Variolin A and N(3’)-methyl tetrahydrovariolin B. Tetrahedron 1994, 50, 3993–4000.
24. Lagoja, I.M. Pyrimidine as constituent of natural biologically active compounds. Chem. Biodiver. 2005, 2, 1–50.
25. Urban, S.; Hickford, S.J.H.; Blunt, J.W.; Munro, M.H.G. Bioactive Marine Alkaloids. Curr. Org. Chem. 2000, 4, 765–807.
26. Fresneda, P.M.; Delgado, S.; Francesch, A.; Manzanares, I.; Cuevas, C.; Molina, P. Synthesis and cytotoxic evaluation of new derivatives of the marine alkaloid Variolin B. J. Med. Chem. 2006, 49, 1217–1221.
27. Anderson, R.J.; Morris, J.C. Total synthesis of variolin B. Tetrahedron Lett. 2001, 42, 8697–8699.
28. Anderson, R.J.; Morris, J.C. Studies toward the total synthesis of the variolins: Rapid entry to the core structure. Tetrahedron Lett. 2001, 42, 311–312.
29. Ahaidar, A.; Fernández, D.; Danelón, G.; Cuevas, C.; Manzanares, I.; Albericio, F.; Joule, J.A.; Álvarez, M. Total syntheses of Variolin B and Deoxyvariolin B. J. Org. Chem. 2003, 68, 10020–10029.
30. Ahaidar, A.; Fernández, D.; Pérez, O.; Danelón, G.; Cuevas, C.; Manzanares, I.; Albericio, F.; Joule, J.A.; Álvarez, M. Synthesis of variolin B. Tetrahedron Lett. 2003, 44, 6191–6194.
31. Molina, P.; Fresneda, P.M.; Delgado, S. Carbodiimide-mediated reparation of the Tricyclic pyrido[3′,2′:4,5]pyrrolo[1,2-c]pyrimidine ring system and its application to the synthesis of the potent antitumoral marine alkaloid Variolin B and analog. *J. Org. Chem.* **2003**, *68*, 489–499.

32. Molina, P.; Fresneda, P.M.; Delgado, S.; Bleda, J.A. Synthesis of the potent antitumoral marine alkaloid Variolin B. *Tetrahedron Lett.* **2002**, *43*, 1005–1007.

33. Baeza, A.; Mendiola, J.; Burgos, C.; Álvarez-Builla, J.; Vaquero, J.J. Palladium-mediated C–N, C–C, and C–O functionalization of azolopyrimidines: A new total synthesis of Variolin B. *Tetrahedron Lett.* **2008**, *49*, 4073–4077.

34. Álvarez, M.; Fernández, D.; Joule, J.A. Synthesis of deoxyvariolin B. *Tetrahedron Lett.* **2001**, *42*, 315–317.

35. Anderson, R.J.; Hill, J.B.; Morris, J.C. Concise Total Syntheses of Variolin B and Deoxyvariolin B. *J. Org. Chem.* **2005**, *70*, 6204–6212.

36. Butler, M.S.; Capon, R.J.; Lu, C.C. Psammopemmins (A–C), novel brominated 4-hydroxyindole alkaloids from an Antarctic sponge, *Psammopemma* sp. *Aust. J. Chem.* **1992**, *45*, 1871–1877.

37. Reyes, F.; Fernández, R.; Rodríguez, A.; Francesch, A.; Taboada, S.; Ávila, C.; Cuevas, C. Aplicyanins A–F, new cytotoxic bromoindole derivatives from the marine tunicate *Aplidium cyanenum*. *Tetrahedron* **2008**, *64*, 5119–5123.

38. Sísa, M.; Pla, D.; Altuna, M.; Francesch, A.; Cuevas, C.; Albericio, F.; Álvarez, M. Total Synthesis and Antiproliferative Activity Screening of (±)-Aplicyanins A, B and E and Related Analogues. *J. Med. Chem.* **2009**, *52*, 6217–6223.

39. Bialonska, D.; Zjawiony, J.K. Aplysinopsins—Marine indole alkaloids: Chemistry, bioactivity and ecological significance. *Mar. Drugs* **2009**, *7*, 166–183.

40. Mancini, I.; Guella, G.; Zibrowius, H.; Pietra, F. On the origin of quasi-racemic alysinospin cycloadducts, (bis)indole alkaloids isolated from scleractinian corals of the family Dendrophylliidae. Involvement of enantiodefective Diels–Alderases or asymmetric induction in artifact processes involving adventitious catalysts? *Tetrahedron* **2003**, *59*, 8757–8762.

41. Guella, G.; Mancini, I.; Zibrowius, H.; Pietra, F. Novel alysinospin-type alkaloids from scleractinian corals of the family Dendrophylliidae of the Mediterranean and the Philippines. Configurational-assignment criteria, stereospecific synthesis, and photoisomerization. *Helv. Chim. Acta* **1988**, *71*, 773–782.

42. Guella, G.; Mancini, I.; Zibrowius, H.; Pietra, F. Alysinospin-type alkaloids from *Dendrophyllia* sp., a scleractinian coral of the family Dendrophylliidae of the Philippines. Facile photochemical (Z/E) photoisomerization and thermal reversal. *Helv. Chim. Acta* **1989**, *72*, 1444–1450.

43. Fattorusso, E.; Lanzotti, V.; Magni, S.; Novellino, E. Tryptophan derivatives from a Mediterranean anthozoan, *Astroides calycularis*. *J. Nat. Prod.* **1985**, *48*, 924–927.

44. Iwagawa, T.; Miyazaki, M.; Okumara, H.; Nakatani, M.; Doe, M.; Takemura, K. Three novel bis(indole) alkaloids from a stony coral *Tubastraea* sp. *Tetrahedron Lett.* **2003**, *44*, 2533–2535.

45. Koh, E.G.L; Sweatman, H. Chemical warfare among scleractinians: Bioactive natural products from *Tubastraea faulkneri* Wells kill larvae of potential competitors. *J. Exp. Mar. Biol. Ecol.* **2000**, *251*, 141–160.

46. Hu, J.-F.; Schetz, J.A.; Kelly, M.; Peng, J.-N.; Ang, K.K.H.; Flotow, H.; Leong, C.Y.; Ng, S.B.; Buss, A.D.; Wilkins, S.P.; Hamann, M.T. New antiinfective and human 5-HT2 receptor binding
natural and semisynthetic compounds from the Jamaican sponge *Smenospongia aurea*. *J. Nat. Prod.* **2002**, *65*, 476–480.

47. Aoki, S.; Ye, Y.; Higuchi, K.; Takashima, A.; Tanaka, Y.; Kitagawa, I. Novel neuronal Nitric Oxide Synthase (nNOS) selective inhibitor, Aplysinopsin-type indole alkaloid, from marine sponge *Hyrtios erecta*. *Chem. Pharm. Bull.* **2001**, *49*, 1372–1374.

48. Segraves, N.L.; Crews, P. Investigation of brominated tryptophan alkaloids from two Thorectidae sponges: *Thorectandra* and *Smenospongia*. *J. Nat. Prod.* **2005**, *68*, 1484–1488

49. Djura, P.; Stierle, D.B.; Sullivan, B.; Faulkner, D.J. Some metabolites of the marine sponges *Smenospongia aurea* and *Smenospongia* (*Polyfibrospongia*) *echina*. *J. Org. Chem.* **1980**, *45*, 1435–1441.

50. Murata, M.; Miyagawa-Kohshima, K.; Nakanishi, K.; Naya, Y. Characterization of compounds that induce symbiosis between sea anemone and anemone fish. *Science* **1986**, *234*, 585–587.

51. Okuda, R.K.; Klein, D.; Kinnel, R.B.; Li, M.; Scheuer, P.J. Marine natural products: The past twenty years and beyond. *Pure Appl. Chem.* **1982**, *54*, 1907–1914.

52. Landolt, H.-P.; Wehrle, R. Antagonism of serotonergic 5-HT2A/2C receptors: Mutual improvement of sleep, cognition and mood? *Eur. J. Neurosci.* **2009**, *29*, 1795–1809.

53. Giorgetti, M.; Tecott, L.H. Contributions of 5-HT2C receptors to multiple actions of central serotonin systems. *Eur. J. Pharmacol.* **2004**, *488*, 1–9.

54. Koha, E.G.L.; Sweatmanb, H. Chemical warfare among scleractinians: Bioactive natural products from *Tubastraea faulkneri* wells kill larvae of potential competitors. *J. Exp. Mar. Biol. Ecol.* **2000**, *251*, 141–160.

55. Carroll, A.R.; Avery, V.M. Leptoclzinidamines A-C, indole alkaloids from the Australian Ascidian *Leptoclinides durus*. *J. Nat. Prod.* **2009**, *72*, 696–699.

56. Chevolot, L.; Chevolot, A.-M.; Gajhede, M.; Larsen, C.; Anthoni, U.; Christophersen, C. Chartellamide A: A pentahalogenated alkaloid from the marine bryozoan *Chartella papyracea*. *J. Am. Chem. Soc.* **1985**, *107*, 4542–4543.

57. Anthoni, U.; Bock, K.; Chevolot, L.; Larsen, C.; Nielsen, P.H.; Christophersen, C. Chartellamide A and B, halogenated β-lactam indole-imidazole alkaloids from the marine bryozoan *Chartella papyracea*. *J. Org. Chem.* **1987**, *52*, 5638–5639.

58. Rahbaek, L.; Anthoni, U.; Christophersen, C.; Nielsen, P.H.; Petersen, B.O. Marine alkaloids. 18. Securamines and Securines, halogenated indole-imidazole alkaloids from the marine bryozoan *Securiflustra securifrons*. *J. Org. Chem.* **1996**, *61*, 887–889.

59. Rahbaek, L.; Christophersen, C. Marine alkaloids. 19. Three new alkaloids, Securamines E-G, from the marine bryozoan *Securiflustra securifrons*. *J. Nat. Prod.* **1997**, *60*, 175–177.

60. Seldes, A.M.; Brasco, M.F.R.; Franco, L.H.; Palermo, J.A. Identification of two meridians from the crude extract of the tunicate *Aplidium meridianum* by tandem mass spectrometry. *Nat. Prod. Res.* **2007**, *21*, 555–563.

61. McKay, M.J.; Carroll, A.R.; Quinn, R. J.; Hooper, J.N.A. 1,2-Bis(1H-indol-3-yl)ethane-1,2-dione, an indole alkaloid from the marine sponge *Smenospongia* sp. *J. Nat. Prod.* **2002**, *65*, 595–597.

62. Fusetani, N.; Asano, M.; Matsunaga, S.; Hashimoto, K. Bioactive marine metabolites—XV. Isolation of alysinosinpsin from the scleractinian coral *Tubastrea aurea* as an inhibitor of development of fertilized sea urchin eggs. *Comp. Biochem. Physiol.* **1986**, *85B*, 845–846.
63. Stanovnik, B.; Svete, J. The synthesis of aplysinopsins, meridianines, and related compounds. *Mini-Rev. Org. Chem.* **2005**, *2*, 211–224.

*Sample Availability:* Available from the authors.

© 2010 by the authors; licensee MDPI, Basel, Switzerland. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).